SG/PUT/VERTEX PHARMACEUTICALS/500/0.1/17.01.25 | Market Closed - Börse Stuttgart 07:32:56 28/06/2024 BST | ||
| 4.46 EUR | +0.68% |
|
| Current month | -28.87% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 4.46 | +0.68% |
| 27/06/24 | 4.43 | -3.28% |
| 26/06/24 | 4.58 | +5.53% |
| 25/06/24 | 4.34 | -7.86% |
| 24/06/24 | 4.71 | +1.51% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 07:32 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SY01DA |
| ISIN | DE000SY01DA9 |
| Date issued | 29/05/2024 |
| Strike | 500 $ |
| Maturity | 17/01/2025 (202 Days) |
| Parity | 10 : 1 |
| Emission price | 5.48 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.44 € |
|---|---|
| Lowest since issue | 4.07 € |
| Spread | 0.04 € |
| Spread % | 0.83% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Warrants
- Warrant
